Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Wednesday, September 21, 2022
WuXi Biologics announced that its two Drug Substance (DS) facilities and a Drug Product (DP) facility located in Wuxi city received regulatory approvals from the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).
read more
Tuesday, February 12, 2019
WuXi Biologics and Amicus Therapeutics announced that the companies have entered into an exclusive commercial manufacturing partnership for Amicus' Pompe biologic ATB200.
read more
Thursday, August 08, 2024
WuXi Biologics and Medigene AG announced that they have entered into a three-year, multi-target strategic partnership to design and co-research T cell receptor (TCR)-guided T Cell Engagers (TCR-TCEs) for the treatment of difficult-to-treat tumors.
read more
Thursday, January 29, 2026
WuXi Biologics and Sinorda Biomedicine announced a strategic collaboration for the development and manufacturing of SND006, a novel bispecific antibody, for the potential treatment of inflammatory bowel disease (IBD) and other autoimmune diseases.
read more
Tuesday, February 03, 2026
WuXi Biologics has signed a license and research service agreement with Vertex Pharmaceuticals for an innovative trispecific T-cell Engager (TCE) for the treatment of B-cell mediated autoimmune diseases.
read more
WuXi Biologics announced that the first GMP campaign in the new MFG3 facility was completed successfully.
read more
Wednesday, August 23, 2017
WuXi Biologics announces its unaudited interim results for the six months ended June 30, 2017.
read more
Tuesday, January 16, 2024
WuXi Biologics announced that its Research Service Unit has signed a research service agreement with BioNTech SE.
read more
WuXi Biologics has kicked off construction of its new microbial manufacturing site for commercial production in the Wenjiang district of Chengdu, a hub for pharmaceutical development.
read more
Wednesday, October 31, 2018
WuXi Biologics announced that construction has commenced on a Biologics Manufacturing Center of excellence (MFG8), in the city of Shijiazhuang, one hour train from Beijing.
read more
Friday, September 23, 2016
WuXi Biologics, an open-access R&D capability and technology platform company dedicated to biologics and a WuXi AppTec company, has announced the opening of a new commercial-scale cGMP biologics perfusion manufacturing facility in Wuxi city, China.
read more
Monday, September 28, 2026
WuXi Biologics said its drug-substance and drug-product manufacturing facilities at the Wuxi Mashan site completed a two-week, unannounced FDA inspection of their compliance with good manufacturing practice requirements.
read more
Tuesday, December 02, 2025
WuXi Biologics announced that it has signed a strategic Memorandum of Understanding (MoU) with the Qatar Free Zones Authority (QFZ) to extend WuXi Biologics' global network and capabilities to the Middle East.
read more
Monday, November 01, 2021
WuXi Biologics a global company with leading open-access biologics technology platforms, announced it has successfully launched the GMP operation of its new drug product facility located in Wuxi, China, which is the eighth operational drug product ...
read more
Tuesday, October 17, 2023
WuXi Biologics has launched a new proprietary bioprocessing platform WuXiUI™, an ultra-intensified, fed-batch solution that enhances the productivity and quality of multiple different CHO or other mammalian cell lines and product modalities.
read more